Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tau Imaging With JNJ067
NCT03926702Phase 1Completed
- Sponsor
- University of California, Berkeley
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F] JNJ-64326067 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and progressive supranuclear palsy (PSP), sponsored by University of California, Berkeley. Primary endpoint: Positron-emission tomography scan results at 3 hours. Started Jun 2019; status: completed.
02
Drugs
[18F] JNJ-64326067
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT03926702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926702.